The BRI3BP Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of Jurkat T-lymphocyte cells carrying a targeted disruption of the BRI3BP gene. This heterogeneous knockout model provides a loss-of-function system for investigating the role of the mitochondrial BRI3BP protein in negative regulation of intrinsic apoptosis. By abolishing BRI3BP expression across a polyclonal cell pool, the product enables functional interrogation of how this inhibitor governs cytochrome c release and downstream caspase activation in a human T-cell context. The genetically altered cells are suitable for comparative studies alongside wild-type Jurkat controls, facilitating dissection of apoptotic signaling networks.
The host Jurkat cell line was originally established from the peripheral blood of a 14-year-old male with acute lymphoblastic leukemia, yielding an immortalized T-cell line widely employed in immunology and cancer biology. Jurkat cells serve as a classical model for T-cell receptor signaling, apoptosis, and immune function, with particular relevance to T-cell leukemia. Their well-characterized apoptotic machinery and rapid proliferation make them an ideal host for CRISPR/Cas9-mediated gene disruption, allowing robust assessment of knockout phenotypes in a disease-relevant background.
BRI3BP localizes to the mitochondrial outer membrane and functions as a negative regulator of the intrinsic apoptotic pathway by suppressing cytochrome c release and preventing assembly of the apoptosome. It interacts with key mitochondrial permeability transition components including VDAC, ANT, and BCL2 family members such as BCL2, BAX, and BAK. Upstream signals like DNA damage or growth factor withdrawal typically overcome BRI3BP-mediated inhibition, but its knockout renders cells hypersensitive to such stimuli, leading to accelerated caspase-9 and caspase-3 activation downstream of cytochrome c and Apaf-1. TNF-alpha stimulation further modulates this network through crosstalk with the death receptor pathway.
In the Jurkat T-cell leukemia context, loss of BRI3BP disrupts a critical anti-apoptotic checkpoint, enhancing susceptibility to intrinsic cell death signals. This sensitization is particularly pertinent for studying apoptosis evasion mechanisms that contribute to leukemogenesis and chemoresistance. The polyclonal knockout model recapitulates the genetic heterogeneity often observed in tumor cell populations, making it a valuable tool for probing how variable BRI3BP expression influences cell fate decisions under stress conditions such as therapeutic agent exposure.
This product is engineered for advanced research into mitochondrial apoptosis regulation, T-cell leukemia biology, and drug sensitivity screening. Researchers can employ validated assays such as Western blotting for cleaved caspase-3 and cytochrome c, flow cytometry with Annexin V/PI staining, JC-1 mitochondrial membrane potential measurements, co-immunoprecipitation of BRI3BP complexes, RT-qPCR profiling of apoptosis-related genes, MTT viability tests, and caspase activity assays. Applications span functional dissection of the intrinsic apoptosis pathway, mechanistic studies of apoptosis evasion in lymphoma, and evaluation of novel therapeutics targeting the BCL2 family. For further technical details or ordering information, please contact Ascent Research.
